Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 51 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Evaluation of Test Panel Clear all

Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions: Vicadrostat, Empagliflozin, Placebo matching Vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 208
States / cities: Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more

Conditions: Generalized Pustular Psoriasis
Interventions: Spesolimab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Auburn Hills, Michigan • St Louis, Missouri

Conditions: Opioid Use Disorder
Interventions: BI 1356225, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more

Conditions: Lung Transplant Rejection
Interventions: Belumosudil, Azithromycin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Hepatitis C, Substance Use Disorders
Interventions: HCV GET-Up (Group Evaluation and Treatment Uptake); Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Asthma
Interventions: TEV-56248, Albuterol sulfate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 4 Years and older
Enrollment: 2,769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 157
States / cities: Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more

Conditions: Depressive Disorder, Major
Interventions: BI 1358894, Placebo, Quetiapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 11 more

Conditions: Atopic Dermatitis Eczema
Interventions: Metal Panel T.R.U.E. Test; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests, Telemedicine, Time of Death, Time Perception, Time Reaction, Time Efficiency, Time Management, Population, Population Groups, Epidemic Disease, Pandemic, Sex Behavior, Sex Characteristics, Sex Hormone, Cardio-pulmonary, Surgical, Drugs of Abuse, Health Risks, Clinical Outcomes
Interventions: No Study-Assigned Intervention; Other
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2076
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: Ralinepag, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more

Conditions: Asthma
Interventions: TEV-48574, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 55
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 47 more

Conditions: Dermatitis, Contact
Interventions: T.R.U.E. Test; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions: Pioglitazone, Pioglitazone placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 65 Years to 83 Years
Enrollment: 3,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 34
States / cities: Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more

Conditions: Healthy, Hepatic Impairment
Interventions: BI 1291583; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Rialto, California • Orlando, Florida • Houston, Texas + 1 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Survodutide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 36
States / cities: Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more

Conditions: Heart Failure
Interventions: vicadrostat, empagliflozin, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 94
States / cities: Mobile, Alabama • Chula Vista, California • Orange, California + 81 more

Conditions: Hepatic Impairment
Interventions: Elacestrant dihydrochloride; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Yucaipa, California • Miami, Florida • San Antonio, Texas

Conditions: Heart Failure
Interventions: vicadrostat, empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 89
States / cities: Beverly Hills, California • Covina, California • Encinitas, California + 75 more

Conditions: Colitis, Ulcerative
Interventions: Golimumab; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: La Jolla, California • National City, California • Denver, Colorado + 12 more

Conditions: Post-Traumatic Stress Disorder
Interventions: BI 1358894, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 37
States / cities: Little Rock, Arkansas • Glendale, California • Long Beach, California + 31 more

Conditions: Chronic Hepatitis C
Interventions: VC-CBCS; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Strep Throat
Interventions: Not listed
Lead sponsor: IND Diagnostic Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Bellevue, Nebraska • Franklin, Tennessee • Smyrna, Tennessee

Search by objective public record fields.

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Metal Panel Allergen Patch Test Study

Clinical Time and Temporal Dynamics Study (CLIN-TIME)

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

Evaluation of the IND One Step Strep A Rapid Test vs. Culture